REGENXBIO Aligns with FDA for Accelerated Approval of NAVSUNLI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- FDA Accelerated Approval Progress: REGENXBIO has aligned with the FDA, confirming that existing NAVSUNLI clinical data is sufficient for consideration under the accelerated approval pathway, eliminating the need for additional patient recruitment or studies, with plans to resubmit the Biologics License Application (BLA) in Q3 2026, significantly shortening the time to market and addressing urgent needs of Hunter syndrome patients.
- Clinical Data Review Meeting: The FDA has requested REGENXBIO to seek a Type A meeting to review existing long-term biomarker and clinical data, emphasizing an expedited review process, which indicates the FDA's commitment to addressing rare disease treatments and could provide the company with quicker market access opportunities.
- Treatment Demand for Hunter Syndrome: MPS II (Hunter syndrome) is an extremely rare neurodegenerative disease affecting approximately 2,000 patients globally, with over 500 new cases annually; the FDA's accelerated approval could provide urgently needed treatment options for this patient population, holding significant social and market implications.
- Strategic Partnership Outlook: Following the strategic partnership announced in January 2025, NAVSUNLI is set to be commercialized by NS Pharma in the U.S. upon potential FDA approval, with REGENXBIO retaining all rights and proceeds related to the Priority Review Voucher (PRV), further enhancing the company's market competitiveness and financial outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.900
Low
19.00
Averages
29.71
High
45.00
Current: 7.900
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regenxbio Shares Surge After FDA Reversal on Drug Rejection
- Stock Surge: Regenxbio (RGNX) shares soared by as much as 37% in premarket trading on Monday, reflecting strong market optimism following the FDA's decision to reverse its rejection of the company's rare disease drug, indicating investor confidence in future growth.
- Refiling Plans: The company intends to refile its application for the Navsunli gene therapy in Q3, with a formal meeting with the FDA expected in July to resolve disputes, paving the way for potential approval and market entry.
- Accelerated Approval Pathway: Regenxbio outlined a potential accelerated approval pathway for RGX-202 in 2027 based on pivotal Phase III primary endpoint results, which could further bolster investor confidence in the company's future performance.
- Positive Market Reaction: The FDA's reversal not only boosted Regenxbio's stock price but may also attract more investor interest, enhancing the company's competitiveness and market share in the biopharmaceutical sector.
See More
Regenxbio Plans to Resubmit Navsunli Application
- Resubmission Plan: Regenxbio intends to resubmit its Navsunli application in Q3, with this gene therapy aimed at replacing the faulty gene responsible for Hunter syndrome, which could significantly enhance the quality of life for patients if approved.
- Accelerated FDA Review: CEO Curran Simpson indicated that the FDA might expedite the review process post-resubmission, with a potential review timeline of as little as two months, thereby providing the company with quicker market access opportunities.
- Positive Market Reaction: Following the FDA's agreement to reconsider the Navsunli application, Regenxbio's shares surged 12% in pre-market trading, reflecting strong investor confidence in the therapy, despite a 44% decline in stock price this year.
- Impact of Hunter Syndrome: Hunter syndrome affects approximately 2,000 individuals globally, primarily boys, leading to progressive neurological decline; if Navsunli is approved, it would offer a revolutionary treatment option for this niche market.
See More
REGENXBIO Aligns with FDA for Accelerated Approval of NAVSUNLI
- FDA Accelerated Approval Progress: REGENXBIO has aligned with the FDA, confirming that existing NAVSUNLI clinical data is sufficient for consideration under the accelerated approval pathway, eliminating the need for additional patient recruitment or studies, with plans to resubmit the Biologics License Application (BLA) in Q3 2026, significantly shortening the time to market and addressing urgent needs of Hunter syndrome patients.
- Clinical Data Review Meeting: The FDA has requested REGENXBIO to seek a Type A meeting to review existing long-term biomarker and clinical data, emphasizing an expedited review process, which indicates the FDA's commitment to addressing rare disease treatments and could provide the company with quicker market access opportunities.
- Treatment Demand for Hunter Syndrome: MPS II (Hunter syndrome) is an extremely rare neurodegenerative disease affecting approximately 2,000 patients globally, with over 500 new cases annually; the FDA's accelerated approval could provide urgently needed treatment options for this patient population, holding significant social and market implications.
- Strategic Partnership Outlook: Following the strategic partnership announced in January 2025, NAVSUNLI is set to be commercialized by NS Pharma in the U.S. upon potential FDA approval, with REGENXBIO retaining all rights and proceeds related to the Priority Review Voucher (PRV), further enhancing the company's market competitiveness and financial outlook.
See More
REGENXBIO Aligns with FDA for Accelerated Approval of NAVSUNLI
- FDA Accelerated Approval: REGENXBIO has aligned with the FDA, confirming that existing NAVSUNLI clinical data is sufficient for accelerated approval, thus expediting the treatment process for rare diseases without the need for additional patient recruitment or studies.
- BLA Resubmission Plan: The company expects to resubmit the Biologics License Application (BLA) in Q3 2026 and plans to hold a Type A meeting in July to review existing long-term biomarker and clinical data, ensuring a swift progression of the approval process.
- Market Demand Response: Hunter syndrome is a severe neurodegenerative disease affecting approximately 2,000 patients globally, and the FDA's accelerated approval could provide hope for patients urgently needing new treatment options, addressing the market's demand for innovative therapies.
- Strategic Partnership Outlook: If NAVSUNLI receives FDA approval, REGENXBIO will collaborate with NS Pharma for commercialization in the U.S., potentially leading to the receipt of a Priority Review Voucher (PRV), further enhancing its market position in gene therapy.
See More
FDA Reversal Sparks Biotech Comeback for UniQure and Peers
- FDA Policy Reversal: The FDA's decision to reconsider UniQure's gene therapy candidate AMT-130, with plans to submit a U.S. marketing application in Q3 2026, signifies a potential accelerated approval for Huntington's disease treatment, which could create substantial market opportunities for the company.
- Regenxbio Stock Surge: Following the FDA announcement, Regenxbio's shares surged approximately 23%, positively impacting the future prospects of its gene therapy candidate RGX-121, despite the drug facing FDA rejection in February.
- Replimune's Recovery: Replimune's stock rose about 13%, as the company reached an agreement with the FDA to resubmit its Biologics License Application for RP1, aimed at providing a new treatment option for melanoma patients, demonstrating resilience in the face of adversity.
- Capricor's Continued Growth: Capricor Therapeutics saw its shares increase by around 8%, following the FDA's decision to review its previously rejected candidate Deramiocel for Duchenne muscular dystrophy, resulting in over a 130% rise in stock price over the past year, reflecting increased market confidence in its products.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
Regenxbio Shares Surge After FDA Reversal on Drug Rejection
- Stock Surge: Regenxbio (RGNX) shares soared by as much as 37% in premarket trading on Monday, reflecting strong market optimism following the FDA's decision to reverse its rejection of the company's rare disease drug, indicating investor confidence in future growth.
- Refiling Plans: The company intends to refile its application for the Navsunli gene therapy in Q3, with a formal meeting with the FDA expected in July to resolve disputes, paving the way for potential approval and market entry.
- Accelerated Approval Pathway: Regenxbio outlined a potential accelerated approval pathway for RGX-202 in 2027 based on pivotal Phase III primary endpoint results, which could further bolster investor confidence in the company's future performance.
- Positive Market Reaction: The FDA's reversal not only boosted Regenxbio's stock price but may also attract more investor interest, enhancing the company's competitiveness and market share in the biopharmaceutical sector.
See More
Regenxbio Plans to Resubmit Navsunli Application
- Resubmission Plan: Regenxbio intends to resubmit its Navsunli application in Q3, with this gene therapy aimed at replacing the faulty gene responsible for Hunter syndrome, which could significantly enhance the quality of life for patients if approved.
- Accelerated FDA Review: CEO Curran Simpson indicated that the FDA might expedite the review process post-resubmission, with a potential review timeline of as little as two months, thereby providing the company with quicker market access opportunities.
- Positive Market Reaction: Following the FDA's agreement to reconsider the Navsunli application, Regenxbio's shares surged 12% in pre-market trading, reflecting strong investor confidence in the therapy, despite a 44% decline in stock price this year.
- Impact of Hunter Syndrome: Hunter syndrome affects approximately 2,000 individuals globally, primarily boys, leading to progressive neurological decline; if Navsunli is approved, it would offer a revolutionary treatment option for this niche market.
See More
REGENXBIO Aligns with FDA for Accelerated Approval of NAVSUNLI
- FDA Accelerated Approval Progress: REGENXBIO has aligned with the FDA, confirming that existing NAVSUNLI clinical data is sufficient for consideration under the accelerated approval pathway, eliminating the need for additional patient recruitment or studies, with plans to resubmit the Biologics License Application (BLA) in Q3 2026, significantly shortening the time to market and addressing urgent needs of Hunter syndrome patients.
- Clinical Data Review Meeting: The FDA has requested REGENXBIO to seek a Type A meeting to review existing long-term biomarker and clinical data, emphasizing an expedited review process, which indicates the FDA's commitment to addressing rare disease treatments and could provide the company with quicker market access opportunities.
- Treatment Demand for Hunter Syndrome: MPS II (Hunter syndrome) is an extremely rare neurodegenerative disease affecting approximately 2,000 patients globally, with over 500 new cases annually; the FDA's accelerated approval could provide urgently needed treatment options for this patient population, holding significant social and market implications.
- Strategic Partnership Outlook: Following the strategic partnership announced in January 2025, NAVSUNLI is set to be commercialized by NS Pharma in the U.S. upon potential FDA approval, with REGENXBIO retaining all rights and proceeds related to the Priority Review Voucher (PRV), further enhancing the company's market competitiveness and financial outlook.
See More
REGENXBIO Aligns with FDA for Accelerated Approval of NAVSUNLI
- FDA Accelerated Approval: REGENXBIO has aligned with the FDA, confirming that existing NAVSUNLI clinical data is sufficient for accelerated approval, thus expediting the treatment process for rare diseases without the need for additional patient recruitment or studies.
- BLA Resubmission Plan: The company expects to resubmit the Biologics License Application (BLA) in Q3 2026 and plans to hold a Type A meeting in July to review existing long-term biomarker and clinical data, ensuring a swift progression of the approval process.
- Market Demand Response: Hunter syndrome is a severe neurodegenerative disease affecting approximately 2,000 patients globally, and the FDA's accelerated approval could provide hope for patients urgently needing new treatment options, addressing the market's demand for innovative therapies.
- Strategic Partnership Outlook: If NAVSUNLI receives FDA approval, REGENXBIO will collaborate with NS Pharma for commercialization in the U.S., potentially leading to the receipt of a Priority Review Voucher (PRV), further enhancing its market position in gene therapy.
See More
FDA Reversal Sparks Biotech Comeback for UniQure and Peers
- FDA Policy Reversal: The FDA's decision to reconsider UniQure's gene therapy candidate AMT-130, with plans to submit a U.S. marketing application in Q3 2026, signifies a potential accelerated approval for Huntington's disease treatment, which could create substantial market opportunities for the company.
- Regenxbio Stock Surge: Following the FDA announcement, Regenxbio's shares surged approximately 23%, positively impacting the future prospects of its gene therapy candidate RGX-121, despite the drug facing FDA rejection in February.
- Replimune's Recovery: Replimune's stock rose about 13%, as the company reached an agreement with the FDA to resubmit its Biologics License Application for RP1, aimed at providing a new treatment option for melanoma patients, demonstrating resilience in the face of adversity.
- Capricor's Continued Growth: Capricor Therapeutics saw its shares increase by around 8%, following the FDA's decision to review its previously rejected candidate Deramiocel for Duchenne muscular dystrophy, resulting in over a 130% rise in stock price over the past year, reflecting increased market confidence in its products.
See More
Multiple Companies Experience Significant Stock Price Gains
- CODX Stock Surge: Co-Diagnostics Inc. (CODX) saw a 55% increase in stock price, closing at $3.71, following the completion of its assay development strategy for the Bundibugyo virus, enhancing its market position in the Congo and Uganda.
- AKTX Breakthrough Clinical Data: Akari Therapeutics Plc (AKTX) rose nearly 50% to $5.14 after demonstrating synergistic activity of AKTX-101 with Adagrasib in KRAS-mutated pancreatic cancer models, with a Phase 1 clinical trial expected to start by mid-2027.
- P3 Health Financial Recovery: P3 Health Partners Inc. (PIII) gained over 40%, closing at $13.86, reporting a net income of $3 million for Q1, a significant turnaround from a $44.2 million loss last year, with full-year revenue projected between $1.5 billion and $1.65 billion.
- Sunshine Drug Approval: Sunshine Biopharma Inc. (SBFM) jumped over 40% to $0.51 after receiving approval for its generic Amoxicillin in Canada, expected to ship by August 2026, further expanding its market share.
See More
